Ro, Eli Lilly to streamline patient access to Zepbound single-dose vials

Ro announced earlier that it is working with Eli Lilly (LLY) and Company to streamline access to Zepbound single-dose vials for Ro patients with obesity. The vials will be available as a treatment option with an on-label prescription from a Ro-affiliated provider via an integration with the LillyDirect self-pay pharmacy channel. This offering will make it easier for Ro’s clinically eligible patients to get the FDA-approved, rigorously tested Lilly medicine delivered directly to them at the self-pay price, the company said in a statement. “Offering Zepbound single-dose vials – the most affordable branded incretin medicine by list price – through another platform to LillyDirect will help ensure broader availability of rigorously tested, FDA-approved and regulated obesity treatment,” said Patrik Jonsson, executive vice president, and president of Lilly Cardiometabolic Health and Lilly USA. “Our goal is to break down barriers and provide patients with safe and effective options they can rely on.”